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Severe acute arterial hypertension can be associated with significant morbidity and mortality. After excluding a
reversible etiology, choice of therapeutic intervention should be based on evaluation of a number of factors, such
as age, comorbidities, and other ongoing therapies. A rational pathophysiological approach should then be applied
that integrates the effects of the drug on blood volume, vascular tone, and other determinants of cardiac output.
Vasodilators, calcium channel blockers, and beta-blocking agents can all decrease arterial pressure but by totally
different modes of action, which may be appropriate or contraindicated in individual patients. There is no preferred
agent for all situations, although some drugs may have a more attractive profile than others, with rapid onset
action, short half-life, and fewer adverse reactions. In this review, we focus on the main mechanisms underlying
severe hypertension in the critically ill and how using a pathophysiological approach can help the intensivist decide
on treatment options.
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Arterial hypertension is a worldwide problem, affecting
more than 1 billion people [1,2]. Chronic arterial hyper-
tension is an important cardiovascular risk factor and as-
sociated with significant morbidity and mortality in the
general population [3]. Chronic hypertension also is the
primary risk factor for cerebrovascular disease [4]. Acute
hypertension is not uncommon in the emergency room
or acute care setting [5] and can have important conse-
quences on various organs, including the heart [6], the kid-
neys [7], the brain, and the lungs; associated end-organ
injury has been reported in 19-81% of patients with acute
severe hypertension [8-10]. In a recent American survey of
patients with severe acute hypertension (defined as systolic
arterial pressure [SAP] >180 mmHg and/or diastolic arter-
ial pressure [DAP] >110 mmHg) requiring hospitalization,
new or worsening end-organ dysfunction was observed in
59% of subjects [10]; the 90-day mortality rate was 11%
[10]. More than one third of patients discharged home
were rehospitalized at least once within 90 days, 29% for
acute severe hypertension [11]. Interestingly, 28% of the* Correspondence: jlvincen@ulb.ac.be
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reproduction in any medium, provided the origpatients had a primary neurological diagnosis and mortality
rates were higher in these patients than in those without a
neurological diagnosis (24% vs. 6%, p < 0.0001) [12].
According to general guidelines [1], moderate arterial
hypertension is defined as a systolic arterial pressure
(SAP) ≥140 mmHg or a diastolic arterial pressure (DAP)
≥90 mmHg, also known as Stage I hypertension. This
degree of hypertension is rarely treated in critically ill sub-
jects, unless it is accompanied by obvious harmful hemo-
dynamic symptoms. Stage II hypertension (systolic arterial
pressure [SAP] >160 mmHg or diastolic arterial pressure
[DAP] >100 mmHg [1]) is more frequently associated with
acute cardiovascular complications, including acute heart
failure, intensive care unit (ICU) admission, prolonged hos-
pital stay, and death [1,10,12,13]. Values of SAP >180
mmHg and/or DAP >110 mmHg often are used to define
severe hypertension [10,14].
In discussing hypertension, it is important to differen-
tiate some terms. Hypertensive emergencies are defined
as a marked increase in arterial pressure associated with
acute, life-threatening target-organ injuries (Table 1),
often requiring hospitalization in an ICU for immediate
pressure control. Hypertensive urgencies are not associ-
ated with imminent acute end-organ injury, so that
blood pressure control can be slower, over several hours,. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Most frequent target organs damaged during
acute hypertensive crises
Organ system Example of Injury
Cardiovascular Acute coronary syndromes
Heart failure and pulmonary edema
Aortic dissection
Central nervous system Stroke or transient ischemic attack
Acute encephalopathy/cerebral edema
Retinal hemorrhage
Renal Acute renal failure
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cause there is no consensus regarding the cutoff value of
blood pressure for defining hypertensive urgencies, diag-
nosis should be individualized after taking into account
several factors, such as age, sex, the presence of chronic
hypertension (and use of antihypertensive drugs), and
the presence of comorbidities. Indeed, the same degree
of arterial hypertension may be associated with symp-
toms of acute target-organ damage in one individual or
be completely asymptomatic in another. Nevertheless, in
general terms, a blood pressure equal to or greater than
180/100 mmHg may require intervention [15].
Before initiating therapy for severe acute hypertension
in a critically ill patient, the presence of precipitating
causes should be looked for (Table 2), because removalTable 2 Principal causes of acute systemic arterial












Renal system Urinary retention
Renal failure
Hypervolemia






Intoxication, substance abuse and
overdose (cocaine, phencyclidine,
amphetamines)and/or control of these factors can prevent unnecessary
treatment in many instances. In the patient with chronic
hypertension, it may be wise to continue the antihy-
pertensive medications. Unlike some other traditional
reviews that cover the management of hypertensive ur-
gencies/emergencies in specific diseases (e.g., acute aor-
tic dissection, preeclampsia, cerebrovascular accident)
[16-18], we focus on the main mechanisms underlying
severe hypertension in the critically ill and how a patho-
physiological approach can help the practicing intensivist
to manage this problem.
Review
Pathophysiology of arterial hypertension
Regional blood flow and organ perfusion are determined
by the driving pressure and by vascular autoregulation,
a functional property of vessels that permits blood flow
to adapt to a given level of arterial pressure and tissue
metabolic demand [19,20], thus protecting tissues against
the negative effects of excessive or insufficient flow ob-
served during hypertension and hypotension, respectively.
In healthy subjects, for example, cerebral blood flow is
kept relatively constant through a wide range of arterial
pressures (usually a mean arterial pressure [MAP] from
60-120 mmHg) [5]. Various mechanisms are involved in
vessel autoregulation, including activation of the auto-
nomic system and local production of vasoactive sub-
stances, such as angiotensin II, endothelin, prostanoids,
nitric oxide (NO), adenosine, reactive oxygen species
(ROS), and lactate [21,22]. Endothelial dysfunction also
may contribute to the development of systemic hyperten-
sion. In this respect, preeclampsia, a disease model of
systemic endothelial dysfunction, and some recent chemo-
therapy drugs that inhibit vascular endothelial growth fac-
tor (VEGF), share similar physiological mechanisms for the
genesis of hypertension by inhibiting VEGF, reducing the
production of NO and increasing systemic vascular resist-
ance (SVR) [23].
When faced with a patient with severe acute hyperten-
sion, one needs to keep in mind the two determinants of
arterial pressure [24]:
MAP ¼ COSVR ð1Þ
where CO is the cardiac output. SVR essentially repre-
sents the degree of vascular tone. Because CO is the
product of the heart rate (HR) and the stroke volume
(SV), we can write:
MAP ¼ HRSVð ÞSRV ð2Þ
The vascular tone (SVR) is mainly determined by the
degree of constriction of precapillary and small arterioles
and, to a lesser degree, by the blood viscosity (k). The
vascular tone is an important determinant of ventricular










Nitroglycerin + 0 _ _ _
Nitroprusside + 0 _ _ _ _
Hydralazine +/++ 0 0/+ _ _ _
ACE inhibitors and
AT1 receptor blockers
0 0 _ _ _ _
Calcium channel
blockers
Amlodipine _ _ 0 ++
Nifedipine _ _ 0 + + +
Nicardipine 0 _ 0 +++
Diltiazem _ _ _ 0 +
β−blockers _ _ _ _ _ 0 +
β-blockers with
intrinsic
_ _ 0 0/_
sympathomimetic
activity
Phentolamine 0/ _ _ 0/+ _ _ _
Urapidil 0/+ 0 _ _ _ _ _
Diuretics 0/+ 0 _ _ _ + +
Clonidine _ _ 0 0 _ _
Methyldopa 0/ _ 0/ _ 0/ + _ _
0, no effect; - Slight negative effect; -- moderate negative effect; --- strong
negative effect.
+ Slight positive effect; + + moderate positive effect; + + + strong
positive effect.
ACE angiotensin-converting enzyme, AT1 angiotensin II subtype 1.
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afterload, myocardial contractility, and preload. Preload
is largely determined by the volume status, which is rep-
resented by the central venous pressure (CVP), pulmon-
ary artery occlusion pressure (PAOP), or inferior vena
cava diameter in the clinical setting. Cardiac contractility
is difficult to assess at the bedside but can be indirectly
appreciated by the assessment of the ventricular stroke
work index (basically derived from the product of stroke
index and MAP) and the ejection fraction obtained by
echocardiography [25]. Increased myocardial contractil-
ity can, in principle, contribute to the development of
hypertension, although this would only be observed in
hyperadrenergic conditions.
Combining all these aspects, a final equation for arter-
ial pressure can be derived:
MAP ¼ HR preloadxmyocardial contractility½ ð ÞSVR
ð3Þ
Physicians will be able to manage most cases of severe
hypertension in critically ill patients by associating these
physiological principles with knowledge of the pharma-
cological properties of the available antihypertensive
drugs.
Treatment options for severe acute hypertension in
the ICU
In patients with chronically uncontrolled hypertension,
the circulation in vital organs, such as the brain, heart,
and kidney, adapts, resulting in arteriolar hypertrophy.
These patients are prone to develop organ ischemia
when blood pressure is rapidly reduced, even to levels
considered as relatively high in normotensive patients
[5,26], and one should be particularly cautious when
controlling arterial pressure in such individuals. As a
general rule for the treatment of hypertensive emergen-
cies, one should not try to reduce the MAP by more
than 20% (or diastolic blood pressure by 10-15% or to
approximately 110 mmHg) during the first hour, except
in acute aortic dissection where this goal should be
achieved within 10 min [27].
There are a large number of therapeutic options for
severe hypertension. We will restrict our discussion to
the agents most frequently used in ICU patients (Tables 3
and 4).
Vasodilators
Nitroglycerin Although described as having antihyper-
tensive effects, nitroglycerin causes weak direct arterial
vasodilation, which is observed only with high doses
(>60 μg/min intravenously) [28]. Nitroglycerin has a
more profound venodilating than arteriolar effect. In the
presence of hypovolemia, it may cause a decrease invenous return and CO; in these conditions, reflex tachy-
cardia is common [27]. Nitroglycerin is indicated in se-
vere hypertension associated with volume overload and
pulmonary edema. Nitroglycerin promotes coronary
vasodilation without steal syndrome [29], so that it may
be used at low doses (≤60 μg/min) as an adjunct to other
intravenous antihypertensive agents in patients with
acute coronary syndromes [14]. Nitroglycerin (as other
vasodilators) may increase pulmonary shunt and aggra-
vate systemic hypoxemia by inhibiting pulmonary hyp-
oxic vasoconstriction.
Nitroprusside Sodium nitroprusside is a potent and
short-acting purely vasodilatory agent, causing both ar-
terial and venous vasodilation, thus reducing pre- and
afterload. The rapid onset of action and short half-life
mean that this drug is easily titrated, but because of its
potency, speed of action, and risk of tachyphylaxis,
intraarterial blood pressure monitoring is recommended
[15]. The major unwanted effect if used at high doses for
Table 4 Doses, pharmacokinetics, and pharmacodynamics of the intravenous antihypertensive agents most frequently used in intensive care units











1-3 mg every 2–5 min
(over 1–30 min)
Onset: 5 min Half-life: 3–5 h Metabolism: hepatic
CYP450
Hypotension, heart failure, heart block,
dizziness, fatigue, confusion,
depression, bronchospasm, Raynaud´s
phenomenon, diarrhea, pruritus, rash
Cardiac ischemic syndromes with
arterial hypertension and normal heart
function. Avoid in pheochromocytoma





5 mg every 3 min
(over 1–30 min)
Onset: 5–10 min Half-life: 3–7 h Metabolism: hepatic
CYP2D6
Hypotension, heart failure, heart block,
dizziness, fatigue, depression,
bronchospasm, diarrhea, pruritus, rash
Cardiac ischemic syndromes with
arterial hypertension and normal heart
function
Max dose: 15 mg Duration: 5–8 h Excretion: urine
(5-10% unchanged)
Infusion: not recommended
Labetalol (α1, β1, and
β2-receptor blocker)
Bolus: 20–80 mg every
10 min.
Max dose: 300 mg
Onset: 5–10 min Half-life: 6 h Metabolism: hepatic
glucuronide
conjugation
Nausea, scalp tingling, bronchospasm,
dizziness, heart block, orthostatic
hypotension
Most hypertensive emergencies, good
for hypertension in neurocritically ill
patients and pregnancy; caution in
heart failure







Onset: 1–2 min Half-life: 9 min Metabolism: plasma
esterases
Arterial hypotension, bronchospasm,
heart block, heart failure
Hypertensive emergencies with
normal or high cardiac output, and
aortic dissection in particular.
Contraindicated in
pheochromocytoma crisis












with excessive catecholamine levels







Bolus: 12.5-25 mg Onset: 3–5 min Half-life: 2–4.8 h Metabolism: hepatic Headache, hypotension, dizziness Hypertensive emergencies in
postoperative and pregnant patients

























Bolus: not recommended Onset: 5–10 min Half-life: 12 h Metabolism: Hepatic
CYP450
Eye and mouth dryness, sed tion,
erectile dysfunction, orthost ic
hypotension, bradycardia, d wsiness.
Hypertensive emergencies, particularly
in the context of withdrawal
syndrome and pain
Max dose: 7.2 μg/min
(or 450 μg/2 h)






250-1000 mg every 6-8h Onset: >1 h Half-life: 2 h Metabolism: Hepatic
CYP450 and central
adrenergic neurons
Peripheral edema, fever, dep ession,
sedation, dry mouth, bradyc rdia,
hepatitis, hemolytic anemia, upus-like
syndrome
Hypertensive emergencies, particularly
in pregnant patients. Use limited by
adverse effects
Max dose: 1000 mg
every 6h






Bolus: 1 μg/Kg/min over
10 min (not necessary in
sedated patients)
Onset: 6–15 min Half-life: 2–2.5 h Metabolism: hepatic Hypotension, bradycardia, fe er,
nausea, vomiting, hypoxia, a emia
Hypertensive urgencies associated
with hyperactive delirium or
withdrawal syndrome





Nicardipine Bolus: not recommended Onset: 5–10 min Half-life: 2–4 h Metabolism: hepatic
CYP3A4
Tachycardia, headache, flush g,
peripheral edema, angina, n usea,
AV block, dizziness
Most hypertensive emergencies;
caution in heart failure




Clevidipine Bolus: not recommended Onset: 1–2 min Half-life: 1–15 min Metabolism: plasma
and tissue esterases
Atrial fibrillation, nausea, fev r,




Max dose: 32 mg/h Peak: 3 min Duration: 5–15 min Excretion: urine 63-74
%, feces 7-22%
Infusion: 1–2 mg/h
Diltiazem Bolus: 0.25 mg/Kg
(over 2 min)
Onset: 2–7 min Half-life: 3.4 h Metabolism: hepatic
CYP3A4
Bradycardia, AV block, hypo nsion,
cardiac failure, peripheral ed ma,
headache, constipation, hep tic
toxicity
Hypertensive emergencies associated
with normal heart function and
tachyarrhythmia
Max dose: 15 mg/h Peak: 7–10 min Duration:30 min-




































Table 4 Doses, pharmacokinetics, and pharmacodynamics of the intravenous antihypertensive agents most frequently used in intensive care units (Continued)
ACE inhibitor
Enalaprilat Bolus: 1.25-5 mg every 6 h Onset: 15–30
min
Half-life: 11 h Metabolism: hepatic
biotransformation




with left ventricular dysfunction;
caution in hypovolemia






Bolus: 10–20 mg every 4–6
h
Onset: 5–20 min Half-life: 2–8 h Metabolism: Hepatic
acetylation
Hypotension, tachycardia, headache,




severe hypertension in pregnancy








Bolus: not recommended Onset: 5–10 min Half-life: 5 min Metabolism: Hepatic
methylation
Hypotension, tachycardia, headache,
nausea, facial flushing, angina, ST-T
wave changes, elevated intraocular
pressure
Hypertensive emergencies, especially
severe hypertension in patients with
acute renal failure















cyanide and thiocyanide intoxication,
nausea, flushing, vomiting, muscle
spasm, pulmonary shunt
Hypertensive emergencies, especially
aortic dissection. Caution in renal and
hepatic failure
Max dose: 10 μg/Kg/min
(<1 h)
Peak: 15 min Excretion: urine












those associated with acute coronary
syndrome, volume overload, or
pulmonary edema













those associated hypervolemia and/or
heart failureMax dose: 200 mg/dose or
160 mg/h

























Bolus: 0.5-1 mg/dose up to
2 times/day






those associated with hypervolemia
and/or heart failure
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toxic metabolites, cyanide and thiocyanide, which accu-
mulate more rapidly in the presence of renal and hepatic
failures. Nitroprusside infusion also may alter gas ex-
change by aggravating pulmonary shunt, increase intracra-
nial pressure by inducing vasodilation, induce coronary
steal syndrome by nonselective coronary vasodilation, and
may be associated with spinal ischemia and paralysis dur-
ing thoracic aortic surgery [30]. Nitroprusside is now
rarely used or recommended as a first-line agent; if used,
limited doses and infusion durations are preferred [15,27].Hydralazine Hydralazine is a direct arterial vasodilator
without significant effects on the venous system. Its
mechanisms of action are complex and involve inhib-
ition of calcium influx into vascular smooth muscle cells,
either by cell membrane hyperpolarization or by induc-
tion of cGMP [31,32]. Hydralazine increases heart rate
and has a slight positive inotropic effect. Hydralazine is
indicated for severe hypertension associated with in-
creased SVR, especially in the presence of bradycardia.
However, hydralazine causes a reflex increase in sympa-
thetic tone and can worsen myocardial oxygen con-
sumption, so should be used with caution in patients
with known heart disease (e.g., heart failure, coronary ar-
tery disease, or valvular dysfunction). Fluid retention
resulting from activation of the sympathetic and renin-
angiotensin systems following peripheral vasodilation
can be managed by adding diuretic drugs if needed. Hy-
dralazine can have prolonged antihypertensive effects
and dosage titration can be difficult [33].
Hydralazine has been used for a long-time as a first-
line agent for pregnancy-induced hypertensive disorders,
but there is evidence suggesting that parenteral hydral-
azine may be associated with more adverse outcomes,
including maternal hypotension, placental abruption,
fetal heart rate abnormalities, Cesarean section, stillbirth,
and fetal suffering compared with labetalol and calcium
channel blockers [34,35].Fenoldopam As a specific dopamine type-1 receptor
agonist, fenoldopam increases renal blood flow, stimu-
lates natriuresis and urinary output, and may improve
renal function, so that it may be suitable for the treat-
ment of severe hypertension in patients with renal fail-
ure [36]. Fenoldopam has a rapid onset of action, a
relatively short half-life, no rebound effect, and no nega-
tive effects on cardiac function [37,38], although it also
may be associated with mild tolerance and hypokalemia
after prolonged infusions. Anaphylactic reactions have
been reported in patients with known sulfite sensitivity
because fenoldopam contains a metabisulfite molecule.
It can increase intraocular pressure and thus also iscontraindicated in patients with glaucoma. Fenoldopam
is not currently available in many countries.
Enalaprilat Enalaprilat is an intravenous angiotensin-
converting enzyme (ACE) inhibitor that reduces periph-
eral arterial vasoconstriction caused by angiotensin II.
Its final antihypertensive effect is highly dependent on
the patient’s volume status and plasma renin activity
[39]. Hence, in normo- or hypervolemic patients without
increased angiotensin II levels, enalaprilat will not cause
major hypotension. Conversely, in hypovolemic subjects
with high angiotensin II levels, the antihypertensive ef-
fect can be significant [39]. Enalaprilat may be consid-
ered in severe hypertension associated with heart failure.
Because of its unpredictable effects, long half-life, and risk
of excessive hypotensive response (especially in hypovol-
emic hyperreninemic patients), it is not considered as a
first-line agent for the treatment of acute hypertension.
Enalaprilat is contraindicated in pregnancy [40].
Calcium channel blockers
These drugs inhibit calcium influx through voltage-
sensitive L-type calcium channels in vascular smooth
muscle cells inducing arteriolar vasodilation and redu-
cing SVR. They are divided into two pharmacological
classes: dihydropyridines and nondihydropyridine deriva-
tives. The dihydropyridines (e.g., nifedipine, nicardipine,
amlodipine) are the largest class, and members have
greater vasodilatory potency and less negative chronotropic
activity, making them relatively safe for patients with
hypertension. However, they can be potentially hazardous
in patients with severe heart failure because of the calcium
entry blocking effects. Two agents, nicardipine and
clevidipine, are available for continuous intravenous in-
fusion for the management of arterial hypertension.
Nicardipine is a second-generation dihydropyridine
with high hydrosolubility, and short onset but a rela-
tively long duration of action. Its dosage is weight-
independent, easily titrated, and it promotes cerebral
and coronary vasodilation [41]. Nicardipine has been
used for the treatment of severe hypertension, particu-
larly in the perioperative period [42,43], and has re-
cently been shown to be superior to labetalol in
treating acute severe hypertension in emergency de-
partment patients [44], including those with end-organ
damage [45], and also in critically ill patients [46].
Clevidipine, a third-generation dihydropyridine, is an
ultrashort acting agent. It is metabolized by plasma es-
terases and has few drug interactions, making it useful
for severe hypertension in critically ill patients, particu-
larly those with renal and/or hepatic failure [47,48].
Clevidipine exerts vascular-selective, arterial specific
vasodilation, without negative effects on cardiac func-
tion, because it does not significantly affect preload and
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has been shown to be more effective than other vasodi-
lators, such as sodium nitroprusside and nitroglycerin,
in the control of acute hypertension during the peri-
operative period of cardiac surgery [49,50]. It also has
been reported to be safe and effective in the manage-
ment of acute severe hypertension in patients with acute
heart failure and renal dysfunction [51,52]. Because it is
a fairly new agent, it is relatively expensive compared
with other agents.
The nondihydropyridine derivatives, which include dil-
tiazem and verapamil, are less potent vasodilators but
with significant negative chronotropic activity, making
them less commonly used as antihypertensive drugs.
Beta-blocking agents
β-adrenergic receptor antagonists (β-blockers) inhibit
the action of norepinephrine, epinephrine, and other
sympathomimetic drugs acting on β receptors. As a gen-
eral rule, the greater the degree of β stimulation that
occurs at a given site, the greater the observed effect of
β-blockers.
β-blocking agents primarily decrease blood pressure
by a reduction in cardiac output (through a reduction in
both contractility and heart rate). They also can reduce
renin release by the juxtaglomerular cells, resulting in
less angiotensin II formation, less generation of NO [53],
suppression of the central nervous sympathetic outflow,
alteration of baroreceptor sensitivity, and attenuation of
the peripheral pressor response to catecholamines [54].
β-blockers reduce the risk of cardiovascular disease and
are of particular interest for patients with ischemic car-
diomyopathy, because they reduce myocardial oxygen
consumption and increase coronary blood flow toward
ischemic regions [55]. β-blocking agents should not be
used in isolation in catecholamine-induced severe hyper-
tension seen with pheochromocytoma or stimulant in-
toxication, because the unopposed peripheral α-effect
could further increase blood pressure [17,56]. Obviously,
β-blocking agents must be avoided in situations where a
reduction in oxygen delivery could be problematic.
Various β-blockers are available, with different degrees
of specificity for β1-receptor antagonism, intrinsic sym-
pathomimetic activity, membrane-stabilizing properties,
capacity to induce vasodilation, lipid solubility, half-life,
onset of action, and routes of administration [57]. β-
blocker agents are classified as non-subtype receptor se-
lective (first generation), β1-receptor selective (second
generation), and antagonists with additional cardiovascu-
lar actions (third generation). Some examples are
presented in Table 4. Of particular interest is esmolol, an
ultrashort acting β1-blocker, which is rapidly metabo-
lized by plasma esterases (safe in renal and hepatic fail-
ure) and has a short half-life. Esmolol is a good optionfor the treatment of severe hypertension, because it can
be easily titrated and discontinued in high-risk patients
or if poorly tolerated, e.g., if heart failure, atrioventricu-
lar block or bronchospasm develop [58,59]. Labetalol, an
example of a third generation β-blocker, competitively
inhibits α1 and β receptors, resulting in a decrease in
blood pressure by both vasodilation and reduction of the
sympathetic stimulation of the heart. Labetalol infusion
is useful in the management of hypertensive crises, par-
ticularly in pregnancy-induced hypertensive emergencies
because of its negligible lipid solubility and placental
transfer [35], but should be used with caution in patients
with hepatic failure [60].
Alpha-blocking agents
Phentolamine (peripheral α-receptor antagonist) This
peripheral α-adrenergic receptor blocker has limited use
in the management of severe hypertension because of
the risk of severe hypotension and other adverse effects.
Phentolamine is mainly indicated for the treatment of
hypertensive emergencies associated with excessive cir-
culating catecholamines, such as in pheochromocytoma
crisis or cocaine intoxication [61,62]. It is no longer
available in many countries.
Urapidil This drug combines selective postsynaptic α1-
adrenergic antagonist activity with central antagonism of
serotonin receptors, which gives it a potent vasodilatory
effect reducing both pre- and afterload, as well as caus-
ing pulmonary and renal vasodilation, without any sig-
nificant effect on cardiac function. It is relatively safe
because it does not affect coronary and cerebral blood
flow. Urapidil has a rapid onset of action, with good effi-
cacy. It has been used for the treatment of severe hyper-
tension in the postoperative period and pregnancy but is
contraindicated in patients with aortic isthmus stenosis,
major arteriovenous shunt, and during lactation [63].
Diuretics
Diuretic drugs provoke inhibition of sodium chloride re-
absorption at different sites in the nephron. Because di-
uretics reduce sodium and water load, and consequently
volemia, they are particularly useful for the treatment of
hypertension associated with hypervolemic and edema-
tous states. For blood pressure control, loop of Henle di-
uretics (furosemide and bumetanide) are preferred for
their rapid onset of action and high potency. Furosemide
may have a direct venodilating effect, although this is de-
bated [64].
Diuretics should be used with caution in acute hyper-
tension, because these patients are often hypovolemic.
Use of ACE inhibitors or other vasodilators may abolish
the increment of SVR induced by furosemide [65], and
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esting combination for the long-term treatment of
hypertensive patients.
Centrally acting antihypertensives
Clonidine Clonidine is a centrally acting α2-adrenergic
agonist. It is more frequently used via the oral route, but
an intravenous formulation is available in some coun-
tries. It can be used as an alternative to β−blocking
agents, because it associates some vasodilating proper-
ties with negative chronotropic effects and is not contra-
indicated in heart block or bronchospasm. Clonidine is
particularly indicated in severe hypertension associated
with pain, anxiety, or withdrawal syndromes, because it
has sedative and analgesic-sparing properties [66]. How-
ever, it should be avoided in patients with a reduced
conscious level. Clonidine should be discontinued grad-
ually because of possible rebound hypertension [67]. In
addition, intravenous clonidine can induce a transient
increase in arterial pressure so that close monitoring is
necessary [68]. Clonidine also can be associated with un-
pleasant effects, including dry eye and mouth, excessive
sedation, and postural hypotension. The availability of
other, safer drugs means that clonidine is not used as a
first-line agent for severe acute hypertension [69].
Dexmedetomidine Although primarily a sedative agent,
dexmedetomidine is a selective α2-adrenergic agent with
rapid onset of action and easy titration, which could
contribute to the control of hypertension in withdrawal
syndromes [70].
Methyldopa Initially used in the treatment of eclampsia,
intravenous methyldopa is no longer widely used be-
cause of its adverse effects. An oral formulation is still
available, but the availability of newer drugs with shorter
half-lives and fewer adverse effects has limited its use.
Choosing the most appropriate antihypertensive
treatment in the ICU
There is no ideal drug for the treatment of severe acute
hypertension in all patients and it is only by recognizing
the underlying pathophysiological process and under-
standing the risk-benefit ratio of each medication that the
intensivist will be able to choose the best therapy for the
individual patient. A recent report from the European
registry for Studying the Treatment of Acute hyperTen-
sion (Euro-STAT), including 761 patients treated with
intravenous antihypertensive agents in the emergency de-
partment, perioperative unit, or ICU, reported that nitro-
glycerin was the most commonly used antihypertensive
treatment (40% of patients), followed by urapidil (21%),
clonidine (16%), and furosemide (8%) [8]. However, in aUnited States registry of 1,588 critically ill patients with
acute severe hypertension treated with intravenous ther-
apy, β-blockers were the most frequently used antihyper-
tensive agent (labetalol 32% and metoprolol 17%), followed
by nitroglycerin (15%), hydralazine (15%), nicardipine (8%),
and sodium nitroprusside (5%) [10]. Interestingly, most of
the patients in this survey (64%) required more than one
drug for blood pressure control. These regional differences
are due to several factors, including marketing influences.
Antihypertensive agents for acutely ill patients should
optimally have a rapid onset of action, a short half-life
enabling easy titration, and no adverse effects. For the
patient with less severe hypertension who will need
prolonged treatment, a long-acting antihypertensive may
be started at the same time as the short-acting drug.
Some important clinical issues must be considered be-
fore starting therapy. First, a careful search and correc-
tion of precipitating factors should be made (Table 2).
Second, major neurological problems should be ex-
cluded. In the presence of intracranial hypertension,
every attempt should be made first to control intracra-
nial hypertension before starting antihypertensive drugs,
because a reduction in cerebral perfusion pressure (the
difference between MAP and intracranial pressure) can
precipitate or worsen brain injury. In the presence of
intracranial hypertension, vasodilators are not the best
agents, because an increase in intracranial blood volume
can further increase intracranial pressure. In these cir-
cumstances, β-blocking agents are a good option. Third,
if drug therapy is needed, it must be based on underlying
pathophysiological considerations. For this purpose, one
should consider the most important components of
acute hypertension: blood volume, heart rate, cardiac
function, and vascular tone. Some comorbidities also
must be considered: the best example is the cautious use
of β-blockers in patients with severe chronic obstructive
pulmonary disease or A-V block. Fourth, in all cases, an
abrupt reduction in blood pressure must be avoided. In
general, the reduction in MAP should not exceed 15-20
% in the first 30 to 60 min [27]. A notable exception is
the presence of acute aortic dissection for which faster
(within 15 min) and greater pressure control may be re-
quired [71].
The first question that should then be asked is whether
or not cardiac output is increased. Maintenance of a high
arterial pressure associated with a hyperkinetic state is only
possible when cardiac function is well preserved, because
cardiac work (essentially the product of arterial pressure
and stroke volume) must be unnecessarily increased. These
states are observed when there is hypervolemia and/or in-
creased sympathetic tone. In the presence of hypervolemia,
diuretics are the preferred drugs.
In the presence of increased adrenergic tone, tachycar-
dia is typically present. Withdrawal syndromes are an
Figure 1 Pathophysiological approach to the treatment of acute systemic arterial hypertension in critically ill patients based on the
main determinants of the mean arterial pressure (MAP). HR, heart rate; SVR, systemic vascular resistance; ALI, acute lung injury; ARDS, acute
respiratory distress syndrome; COPD, chronic obstructive pulmonary disease.
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options for the control of hypertension associated with
hyperadrenergic states. If acute reduction in cardiac
output is of concern, a dihydropyridine calcium channel
blocker (e.g., nicardipine, clevidipine) may be preferred,
because these agents have fewer negative effects on the
heart rate and myocardial contractility. These agents
provide an interesting option for the treatment of post-
operative hypertension [28]. If a vasodilating effect is
best avoided (e.g., in the presence of increased intracra-
nial hypertension), clonidine may be a good alternative
to β-blocking agents.
If cardiac output is not increased much, then the in-
crease in arterial pressure is primarily the result of in-
creased vascular tone. In these conditions, vasodilators
are a logical choice. Venous vasodilators (nitroglycerin)
are particularly indicated in the presence of pulmonary
edema (in association with diuretics). Nitroprusside re-
mains a valuable agent on a short-term basis in the pres-
ence of severe heart failure (because it has no negative
inotropic affects). Its balanced effects on the arterial and
venous sides of the vasculature make it more effective
than nitroglycerin. Its main advantage is its very short
half-life, allowing easy titration. Urapidil also may be
considered where it is available.
A proposed treatment strategy based on a patho-
physiological approach is presented in Figure 1.Conclusions
Severe acute hypertension is an interesting hemodynamic
challenge. Whereas fluid refractory hypotension is gener-
ally treated with a single agent (a vasopressor), hyperten-
sion can be treated with a large array of drugs. After
recognition and removal of precipitating factors, drug
therapy should be initiated and guided by a pathophysio-
logical approach, which consists of the identification of
the principal determinants of arterial pressure and a basic
pharmacological knowledge of the most frequently used
antihypertensive agents. This strategy permits rational
management of individual cases and will help to reduce
undesirable side effects resulting from inadequate or in-
appropriate therapy.
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